- |||||||||| Nebido (testosterone undecanoate depot injection) / Bayer
Trial completion date, Trial primary completion date: ALCeP: Androgen for Leydig Cell Proliferation (clinicaltrials.gov) - Sep 26, 2018 P2/3, N=56, Completed, Trial completion date: Oct 2014 --> Jun 2018 | Trial primary completion date: Aug 2013 --> Jun 2017
- |||||||||| Growtropin-II (somatropin biosimilar) - Dong / A
Trial completion: A Clinical Study to Assess the Efficacy and Safety of DA-3002 (clinicaltrials.gov) - Jul 27, 2018 P3, N=58, Completed, Trial completion date: Oct 2014 --> Jun 2018 | Trial primary completion date: Aug 2013 --> Jun 2017 Active, not recruiting --> Completed
- |||||||||| Growtropin-II (somatropin biosimilar) - Dong / A
Trial primary completion date: A Clinical Study to Assess the Efficacy and Safety of DA-3002 (clinicaltrials.gov) - Sep 20, 2017 P3, N=58, Active, not recruiting, Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> May 2018
- |||||||||| Trial completion, Trial primary completion date: Risk of Diabetes in Young Turner Syndrome Patients (clinicaltrials.gov) - Aug 23, 2017
P=N/A, N=120, Completed, Trial primary completion date: Jun 2016 --> May 2018 Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jun 2017
- |||||||||| Norditropin (somatropin) / Novo Nordisk
Trial completion, Enrollment change: Observational Prospective Study on Patients Treated With Norditropin® (clinicaltrials.gov) - Feb 6, 2017 P=N/A, N=21249, Completed, Recruiting --> Completed | N=100 --> 20 | Trial primary completion date: Oct 2016 --> Jul 2016 Enrolling by invitation --> Completed | N=17000 --> 21249
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: Pregnancy Chances in Classic Galactosemia (clinicaltrials.gov) - Sep 13, 2016
P=N/A, N=85, Completed, Recruiting --> Completed | N=20 --> 14 Recruiting --> Completed | N=150 --> 85 | Trial primary completion date: Dec 2015 --> Sep 2016
- |||||||||| Trial completion, Enrollment change: X-chromosome Inactivation, Epigenetics and the Transcriptome (clinicaltrials.gov) - May 25, 2016
P=N/A, N=110, Completed, Recruiting --> Completed | N=60 --> 5 | Trial primary completion date: Oct 2016 --> Oct 2015 Active, not recruiting --> Completed | N=395 --> 110
- |||||||||| Trial completion, Trial primary completion date: Genetic Etiology in Premature Ovarian Insufficiency (clinicaltrials.gov) - Apr 18, 2016
P=N/A, N=100, Completed, Active, not recruiting --> Completed | N=395 --> 110 Recruiting --> Completed | Trial primary completion date: Nov 2015 --> Apr 2016
- |||||||||| minocycline extended release / Generic mfg.
Trial completion, Trial initiation date, Trial primary completion date: Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome (clinicaltrials.gov) - Feb 19, 2016 P=N/A, N=20, Completed, N=300 --> 75 | Recruiting --> Terminated Active, not recruiting --> Completed | Initiation date: Jan 2009 --> Oct 2007 | Trial primary completion date: Nov 2009 --> Nov 2008
- |||||||||| sertraline / Generic mfg.
Trial completion: Trial of Sertraline to Treat Children With Fragile X Syndrome (clinicaltrials.gov) - Jan 28, 2016 P2, N=57, Completed, Active, not recruiting --> Completed | Initiation date: Jan 2009 --> Oct 2007 | Trial primary completion date: Nov 2009 --> Nov 2008 Active, not recruiting --> Completed
- |||||||||| trofinetide (NNZ-2566) / Neuren, Acadia Pharma
Enrollment closed, Enrollment change: A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome (clinicaltrials.gov) - Aug 17, 2015 P2, N=72, Active, not recruiting, Trial primary completion date: Jul 2015 --> Nov 2015 Recruiting --> Active, not recruiting | N=60 --> 72
- |||||||||| sertraline / Generic mfg.
Enrollment closed, Phase classification, Enrollment change, Trial primary completion date: Trial of Sertraline to Treat Children With Fragile X Syndrome (clinicaltrials.gov) - Aug 15, 2015 P2, N=57, Active, not recruiting, Recruiting --> Active, not recruiting | N=60 --> 72 Recruiting --> Active, not recruiting | Phase classification: PN/A --> P2 | N=72 --> 57 | Trial primary completion date: Jul 2014 --> Aug 2015
- |||||||||| Enrollment closed, Trial primary completion date: Prenatal Screening for Down Syndrome With DNAFirst (clinicaltrials.gov) - Jul 17, 2015
P=N/A, N=100, Active, not recruiting, Recruiting --> Active, not recruiting | Phase classification: PN/A --> P2 | N=72 --> 57 | Trial primary completion date: Jul 2014 --> Aug 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jul 2015
- |||||||||| Enrollment closed, Trial primary completion date: X-chromosome Inactivation, Epigenetics and the Transcriptome (clinicaltrials.gov) - Jun 29, 2015
P=N/A, N=395, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Oct 2015
- |||||||||| Trial primary completion date: Genetic Etiology in Premature Ovarian Insufficiency (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=100, Recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Oct 2015 Trial primary completion date: Jan 2015 --> Nov 2015
- |||||||||| trofinetide (NNZ-2566) / Neuren, Acadia Pharma
Trial primary completion date: A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome (clinicaltrials.gov) - Feb 13, 2015 P2, N=60, Recruiting, Trial primary completion date: Jun 2015 --> Sep 2015 Trial primary completion date: Dec 2014 --> Jun 2015
- |||||||||| mavoglurant (AFQ056) / Novartis
Enrollment change, Trial termination: Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome (clinicaltrials.gov) - Dec 9, 2014 P2, N=148, Terminated, N=170 --> 10 | Recruiting --> Terminated; The study treatment failed to demonstrate efficacy in target population in two other clinical studies (CAFQ056B2214 and CAFQ056A2212). N=200 --> 148 | Recruiting --> Terminated; Study treatment AFQ056 failed to demonstrate efficacy in the adult patient with Fragile X Syndrome in 2 other clinical studies (CAFQ056B2214 and CAFQ056A2212)
- |||||||||| Trial primary completion date: Aortopathy in Persons With Bicuspid Aortic Valve, Turner and Marfan Syndrome (clinicaltrials.gov) - Dec 7, 2014
P=N/A, N=60, Recruiting, N=200 --> 148 | Recruiting --> Terminated; Study treatment AFQ056 failed to demonstrate efficacy in the adult patient with Fragile X Syndrome in 2 other clinical studies (CAFQ056B2214 and CAFQ056A2212) Trial primary completion date: Oct 2014 --> Oct 2016
|